Demant A/S (OTCMKTS:WILYY) Cut to Hold at UBS Group

UBS Group downgraded shares of Demant A/S (OTCMKTS:WILYY) from a strong-buy rating to a hold rating in a report published on Wednesday,Zacks.com reports.

A number of other analysts have also recently weighed in on WILYY. Zacks Research upgraded shares of Demant A/S to a “hold” rating in a report on Friday, June 26th. Sanford C. Bernstein cut Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. Finally, Morgan Stanley upgraded Demant A/S from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Demant A/S presently has an average rating of “Moderate Buy”.

Demant A/S Stock Performance

Shares of WILYY opened at $20.66 on Wednesday. The firm’s 50 day moving average is $19.69 and its 200-day moving average is $17.01. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65. Demant A/S has a 12-month low of $13.45 and a 12-month high of $20.98.

About Demant A/S

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.